Status:
COMPLETED
Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will collect prospective data on the safety and tolerability of Xeloda in patients with advanced gastric cancer from every day clinical practice. Documentation of treatment fo...
Eligibility Criteria
Inclusion
- Patients aged \>/=18 years, with metastatic gastric cancer who are available for prospective documentation of their treatment (first-line chemotherapy)
- Informed consent
Exclusion
- Contraindications to Xeloda per the Summary of Product Characteristics (SmPC)
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT02274376
Start Date
August 1 2008
End Date
December 1 2012
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mannheim, Germany, 68167